Equilibrium models are derived and applied to in vivo binding of spiperone in the rat brain. The models express the concentration of the ligand in the striatum and frontal cortex as a function of the accumulation in the cerebellum. The models differ with respect to the descrip tion of specific binding. Nonlinear regression analysis shows that the in vivo specific binding of 3H-Iabeled spip erone in the frontal cortex (mainly serotonergic) can be described by a noninteracting sites model, whereas the specific binding in the striatum (mainly dopaminergic) can best be described by models that lead to sigmoid satura tion curves. These results were tested and partly con firmed by determining the region-of-interest/cerebellar ra dioactivity ratio of ttC-Iabeled N-methylspiperone, with
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To understand the role of dopamine receptors in human brain pathologies and the antipsychotic ac tions of dopamine antagonists, the in vivo charac terization of the dopamine receptor is required. Data obtained from in vitro experiments may not always apply to in vivo situations. The microenvi ronment of the receptor and the affinity and number of available binding sites may be modified during in vitro processing. Recently, such disparities be tween in vivo and in vitro with respect to spiperone and without pretreatment with haloperidol. The estimated Bmax was 32 fmollmg wet tissue in the frontal cortex and -90 fmollmg wet tissue in the striatum. The free plus nonspecific binding of spiperone was similar in the frontal cortex but lower in the striatum than in the cerebellum. The occurrence of sigmoidicity can be best explained by the existence of high-affinity II ow-capacity sites in the cer ebellum rather than mutual interactions of striatal sites. The consequence of the present analysis for positron emission tomography is that the striatallcerebellar activ ity ratio is not an accurate parameter of specific binding features at tracer doses of spiperone or N-methylspiper one. Key Words: Equilibrium models-N-Methylspiper one-Spiperone.
binding to the dopamine D2-receptor in the rat brain have been reported (Bennett and Wooten, 1986; Chugani et al. , 1988) . Since the availability of the new imaging technique of positron emission tomog raphy (PET), a number of modeling studies for the in vivo binding of D2 antagonists in the human and primate brain have been published (Mintun et al. , 1984; Perlmutter et al. , 1986; Wong et al. , 1986a-c; Farde et al. , 1987a; Logan et al. , 1987) . However, these studies have so far failed to clarify the dopa mine D2 densities in the normal and pathological brain (see Andreasen et al. , 1988 ; Waddington, 1989) . Modeling the in vivo ligand accumulation in the rat brain may contribute to an improvement in PET receptor models for the human brain.
The equilibrium models presented in this study were applied to in vivo data of eH]spiperone bind ing in the rat striatum and cerebellum, published by Van der Werf et al. (1984) , and to data from the frontal cortex, which are presented in this article. In the human brain, spiperone and analogues bind ir-reversibly to the dopamine D2-receptor (Wong et aI. , 1986a ) and equilibrium will not occur. How ever, this has not been established for the rat brain. A few in vivo equilibrium studies with eH]spiperone have been published (Ferrero et aI. , 1983; Lesly and Bennett, 1987) . The onset of equilibrium varied from 2 to 4 h in these studies. A bolus administra tion does not lead to a true equilibrium because of the constant clearance of ligand. However, at tracer amounts a pseudoequilibrium, defined as the occur rence of a constant total/free ligand concentration ratio, may occur. The cerebellum (containing, if any, only a few sites) may be used instead of the free ligand, assuming a linear relationship in the drug elimination phase. Thus, a constant tissue/ cerebellum activity ratio may indicate the occur rence of such a pseudoequilibrium state (Farde et aI. , 1987b) . A nearly constant striatum/cerebellum ratio from 30 min to 8 h after injection can be de rived from binding data of eH]spiperone, published by Barone et al. (1985) , and between 2 and 3 h from the data of Chugani et al. (1988; Fig. 7-24 in Huang and Phelps, 1986) . At higher doses the initial appar ent dissociation rate is higher than at tracer doses (see Eq. 4 in Wong et aI. , 1986a) . Therefore, equi librium may be expected to occur earlier at phar macological doses. These considerations have led us to assume that equilibrium has been approxi mately reached 2 h after injection in our experi ments where mainly (sub)saturating doses are ap plied. Spiperone and analogues are poorly metabolized in the brain (Holt et aI. , 1977; Kuhar et aI. , 1978) and metabolites hardly cross the blood-brain bar rier (Arnett et aI. , 1985a,b) . Therefore, because only total tissue accumulations are involved as vari ables in the models, metabolism is not considered. To test some modeling results, we performed in vivo binding experiments with e lC]N-methylspip erone ([IIC]NMSP) in the rat brain. The results are discussed in relation to PET. Our findings were partly and preliminarily reported at the 6th International Catecholamine Symposium, Jerusalem, June 1987 (Swart et aI. , 1988) , and at the EEC/PET workshop, in Brussels, October 1988 (Swart et aI. , 1989) .
THEORY
In vivo the total concentration of a ligand in the regions of interest (ROIs), the striatum and frontal cortex, is assumed to consist of three fractions:
where Lt is the total concentration of the ligand, BL is the concentration of specifically bound ligand, i. e. , bound to receptor sites, L is the concentration of free ligand, and Ln is the concentration of non specifically bound ligand, defined as the pool of ligand that is nonsaturable at the applied dose range and in equilibrium with free ligand: Ln = fL, where I is a constant. It is assumed that 2 h after injection, the vascular concentration is negligible. Equation 1 can be written as
where B is a binding function. Assuming that spe cific binding is negligible in the cerebellum, the total concentration is given by
where the subscript "c" refers to the cerebellum. At equilibrium, the concentrations of free ligand in the tissues are proportional to the vascular concen tration and consequently L = kLc' where k is a constant. Substituting Eq. 3 into Eq. 2 leads to an expression for the overall binding in an ROI in terms of the cerebellar concentration:
The parameter cP = k(1 + j)/(1 + I e ) is the ratio of nonspecifically bound plus free ligand in the ROI and the cerebellum. By substituting the function B(L) in Eqs. 4 and 5 by receptor/ligand interaction models, a set of four nested models, i. e., a smaller model that is a sub model of a larger model (Landaw and DiStephano, 1984) , is derived (see Table 1 ). (Swart et aI. , 1990) . Several other models that share mUltiple interacting sites can formally be de scribed by this model (see Segel, 1975) . The ROI cerebellar sites (RCS) model is based, in contrast to 
Equations of in vivo binding models
The term B(L) in Eq. 5 (see Methods) is substituted for the equations of receptor/ligand interactions to obtain the model equations.
NIS model, noninteracting sites model: specific binding occurs to one class of independent sites according to the classic mass/action law:
IS model, interacting sites model: the specific binding is described by the Hill equation (see, e.g., Segel, 1975; Bennett, 1978) , which describes binding in case of negative (h < 1) or positive (h > 1) cooperativity; COM 1 model, binding to two classes of independent sites (see the NIS model); COM2 model, binding to independent sites (site 1) and to interacting sites (site 2) (see the NIS and IS models, respectively); TIS model, two interacting sites model: the specific binding to two interacting sites occurs according to the Adair-Pauling model (see, e.g. , Segel, 1975) ; RCS model, cerebellar sites model: the specific binding occurs to independent sites in both the region of interest (ROI) and the cerebellum. The model is derived in the Appendix. B(L) = concentration of specifically bound ligand in ROI (fmol/mg); L = concentration of unbound ligand in ROI (fmol/mg); Lt = total concentration of ligand in ROI (fmol/mg); Bmax = concentration of specific binding sites (fmol/mg); Kd = dissociation constant (fmol/mg); h = apparent Hill coefficient;
The indexes "1" and "2" denote different classes of specific sites; the index "c" denotes the cerebellum.
the other models, on the existence of noninteracting sites in both the ROI and the cerebellum. The curve of the ROI versus the cerebellar accumulation is sigmoid under some conditions (see Appendix).
METHODS

Experiments
Data for in vivo spiperone binding from the control site of unilateral kainate-treated rats were used for the anal ysis. Similar Bmax values for spiperone in striatum and frontal cortex were found in nonpretreated control rats (Van der Werf et al., 1984) . The method for the determi nation of in vivo spiperone binding has been described in detail by Van der Werf et al. (1984) . In brief, male Wistar rats (180-220 g) were injected with [ 3 H]spiperone 25 /LCi/kg i. v. The specific activity of the dose was varied from 16 to 0.02 Ci/mmol by adding different amounts of the unlabeled drug. Two hours after injection, the brains were dissected and the ROIs were frozen on dry ice and weighed. The radioactivity in the tissues was measured by a liquid scintillation counter (the efficiency was -40%). The total tissue concentrations of spiperone were derived from the radioactive contents and the specific activity of the dose.
To test the results of the regression analysis also in intact rats and to exclude isotope effects of eH]spip erone, we determined the in vivo accumulation of [llC] _ NMSP in the rat brain.
[IIC]NMSP was prepared accord ing to Burns et al. (1984) by methylation of spiperone with llCH 3 1. The specific activity of the final product as de termined by ultraviolet spectrometry varied from 60 to 360 Ci/mmol. Immediately after the production of [llC]NMSP, 6-week-old male Wistar rats (190-220 g) re ceived the labeled drug (50-1,500 ,..,. . Ci/kg), either pure or mixed with the unlabeled drug (5-100 nmoUkg), via the tail vein. The rats were killed by decapitation 50 min later. Some animals were pretreated with haloperidol (1 mg/kg i.p.) 30-60 min prior to the administration of [llC]NMSP. The striatum, the frontal cortex, and the cer ebellum were dissected as described by Van der Werf et al. (1984) . After dissection the radioactivity was deter mined with an NaI well-type counter and the tissues were weighed. The measured radioactivity was corrected for background and decay.
Data analysis
Analysis of the experimental procedures indicated a standard deviation of the data of fr-7%. The data points were weighed with the reciprocal value of the estimated variance. Nonlinear regression analysis (Dixon, 1985) was applied to fit the models to the data. The programs were run on a CDC 170/760 computer (Groningen Uni versity). A runs test (Sokal and Rohlf, 1981 ) was used to test the randomness of the data points around the regres sion line. An F test (Landaw and DiStephano, 1984) was applied to evaluate the goodness of fit of the models with respect to the weighed residual sum of squares (WRSS) and the number of parameters. Under the null hypothesis that model 1 is correct, the F statistic is given by
where WRSS1 and WRSS2 are the weighted residual sums of squares of residuals of model 1 and 2, respectively. The corresponding degrees of freedom dfl and df2 are defined as df = N -P, where N is the number of data points and P is the number of parameters in the model. In case of equal degrees of freedom, we applied an F test, under the null hypothesis that both models are equivalent: F1 2 = WRSS/WRSS2, with N = P degrees of freedom. An initial positive slope of the plot of the ROIl cerebellum activity ratio versus the cerebellar binding or versus the applied dose indicates sigmoid binding . To test the occurrence of such an initially rising curve, the ROIlcerebellar radioactivity ratio of [llC]NMSP was plotted versus the dose. Polynomial re gression was applied to determine a possible peak. Spear man's rank correlation test (Sokal and Rohlf, 1981 ) was used to test the positive ranking of the data points before this peak.
RESULTS
Regression analysis
The statistics of the regression analysis of spip erone binding in the striatum and frontal cortex are given in Table 2 . The WRSS values of the models applied to the frontal cortical data are very similar. In addition, the runs test shows no significant (p > 0. 05) deviation from randomness of the data points around the regression line for all models. The F test indicates the NIS model as the model of choice for the frontal cortical data.
The WRSS values from the striatal data are much more variable. The runs test shows a significant de viation from randomness of the data points around the regression lines based on the NIS and COM1 model. This indicates a poor description of the data by these models. Comparison of the four nested models (NIS, IS, COM1, and COM2) leads to the IS model as the model of choice (Table 2) . No signif icant improvement of the goodness of fit (p > 0. 1) was found for the the TIS as compared to the IS model. These two models should therefore be con sidered as statistically equivalent. The goodness of fit of the RCS as compared to the IS model is im proved, but not very significantly (0. 1 > P > 0. 05). The COM2 model does not lead to an improvement of fit as compared to the other sigmoidal models. In addition, the estimated parameter values of this lat ter model (Table 3) have relatively high standard deviations, indicating overparameterization. These results indicate the sigmoidal IS model as the model of choice for the empirical description of the striatal binding data. Both the TIS and the RCS models are interpretations of the IS model, but the TIS model is somewhat preferred from a statistical point of view. The striatal and frontal cortical binding data and the corresponding curves of the NIS and IS models are plotted versus the cerebellar binding (Fig. 1) . The inflection point of the striatal curve appears at a value of [1.91, 13. 14] (see the inset in Fig. 1A) . The early part of the curve of the striatal NIS model in the inset demonstrates the poor fit of this model. The tissue/cerebellum ratios are plotted in Fig. 2 . A peak-shaped curve appears for the striatum but not for the frontal cortex.
Parameter estimation
The striatal B m ax values are 93, 80, and 89 fmol/ mg, as derived from the IS, TIS, and RCS models, respectively ( Table 3 ). The Hill coefficient (I S model) is 1. 34 and the interaction factor (TI S model) is 13. 6, as is demonstrated by the sigmoid The models are specified in Table ! and the Appendix. The F statistics are defined in Methods; the models in the left column are tested versus the models in the top row. The null hypothesis is that the model in the left column is correct except for the underlined values where the null hypothesis is that both models are equivalent. The rectangles denote the set of nested models that are considered separately from the other two models; see the text. WRSS, weighted residual sum of squares; df, degrees of freedom [number of data points (28) minus number of parameters in the model (3-6)]. a p < 0.05. b P < 0.001. The models and parameters are specified in Table 1 and the Appendix. The estimates of the parameters and (asymptotic) standard deviation are provided by the BMDP nonlinear regression procedures.
a Very high SD (>2,000).
curvature in Fig. 1 . The latter value indicates, ac cording to the Adair-Pauling interpretation, a 13-to 14-fold increase of the affinity when one site be comes occupied. The cerebellar B m ax (RCS model) is 3 fmollmg, <3% of the striatal density. The PIP c value of 5 indicates that these cerebellar sites have a higher affinity than the striatal sites. In contrast to the frontal cortex, the striatal value of <I> is lower than unity (Table 3) , indicating different kinetics for the nonspecifically bound plus free ligand in these regions. The estimated frontal cortical B m ax is 31 fmollmg ( Table 2 ).
Binding of [llC]NMSP
The tissue/cerebellum actIVIty ratios of e lC]_ NMSP in the rat striatum and frontal cortex are plotted against the dose in Fig. 3 . Polynomial re gression analysis revealed a peak for the striatal data (Fig. 3A) at a dose of 27 nmol/kg. The plot has a significant initially rising slope (p < 0.002). Pre treatment with haloperidol resulted in complete dis appearance of the peak, although the specific bind ing was not completely reduced. A small but signif icant peak was found for the frontal cortical data (Fig. 3B ) at a dose of 17 nmollkg tissue. Data points of the frontal cortex of haloperidol-treated rats ap pear to differ only slightly from those of untreated rats.
DISCUSSION
In vivo binding models
The models presented in this study are inherently nonlinear. They cannot be linearized according to classic approaches as, e. g. , the double-reciprocal plot, because of the extra component of free plus nonspecifically bound ligand. Therefore, we applied multiple modeling and nonlinear regression with re spect to the same data set to test different binding equations and to estimate the parameters of inter est. All models express the total binding in an ROI as a function of the total binding in a reference tis sue at equilibrium. This makes our approach suit able for clinical PET studies when equilibrium con ditions are reached, e. g. , by using the dopamine D2 antagonist raclopride in humans (Farde et al. , 1986 (Farde et al. , , 1987a .
Fitting results
The frontal cortical binding can be described by the non sigmoid NIS model, and more complex models do not lead to an improved fit. In contrast, considering the four nested models, the striatal data are best described by the sigmoid IS model. Spip erone binding is predominantly serotonergic in the frontal cortex and dopaminergic in the striatum (Pedigo et aI. , 1978; Howlett and Nahorski, 1980; Marchais et aI. , 1980; Seeman, 1980; List and See man, 1981; Liskowsky and Potter, 1985) . That most striatal sites are of one type is supported by the finding that in the striatum the accumulation of spiperone (up to 75 fmollmg) correlates linearly with acetylcholine level; this relationship is abol ished after denervation of the dopaminergic input (Korf et aI. , 1985; Korf and Sebens, 1987) . The es timated striatal B m ax is in accordance with a number of in vivo studies (see, e. g. , Seeman, 1987) but rel- Table 3 and models de scribed in Table 1 . Inset: Sigmoid cur vature of the striatal IS model at the early part of the abscissa. The dashed line is the regression curve of the stri atal NIS model. peak for the nontreated animals at a dose of 27 nmol/kg wet tissue for the striatal data and 17 nmol/kg for the frontal cortical data. The data points before that peak are positively ranked: p < 0.002 (n = 28) for the striatal ratios and p < 0.01 (n = 7) for the frontal cortical ratios. Pretreatment with halo peridol leads to a complete disappearance of the striatal peak but not to a complete reduction of binding. No rank correlation after haloperidol treatment between the ratio and the dose was found. A few pretreated frontal cortical data points were produced; these cases differ only slightly from the nontreated cases.
atively high as compared to most values found in vitro. Even if the present B m ax is corrected for se rotonergic sites (�15-30%) (see Howlett and Na horski, 1980; Seeman, 1980; List and Seeman, 1981) , it is still about twice most in vitro values (�30 fmollmg) (see Seeman, 1980 Seeman, , 1987 . It was sug gested by Seeman (1987) that high in vivo densities are caused by taking the cerebellar binding as the baseline. However, in the present and previous (Van der Werf et aI., 1984) study, the cerebellar binding is used as an independent variable instead of a baseline. Our striatal B m ax is much higher than that, also determined in vivo, reported by Lesly and Bennett (1987) . However, their method may lead to a decrease of sites by processing the samples, as may occur in in vitro assays. At higher doses, all models reduce to the linear function Lt = <flLtc + B m ax. As a consequence, higher doses determine the B m ax value rather strongly. Thus, even if our equilibrium approach is not entirely appropriate for the analysis, the B m ax derived from the ordinate in tercept of the asymptote to which the data tend in Pig. 1 is still rather high as compared to in vitro. Chugani et ai. (1988) showed evidence for the ex istence of an extra pool of agonist-mediated inter nalized sites in vivo, determined by eH]spiperone . This extra pool may explain the rather high densi ties found in the present study. The striatal nonspecific binding is, in contrast to the frontal cortex, much lower than the cerebellar binding. It emphasizes that care must be exercised to use the cerebellar binding as an estimate of the fraction of free plus nonspecifically bound ligand in other tissues.
A Hill coefficient of 1.34 (IS model) in the stria tum indicates at least two interacting populations of sites as is represented by the TIS model. Although there is some evidence for the existence of multiple subunits of the dopamine D2-receptor (Gredal and Nielsen, 1987; Jarvie et aI., 1988) , no direct evi dence for mutual binding interactions of spiperone has been reported yet. Another interpretation is represented by the RCS model: the existence of high-affinity/low-capacity sites in the cerebellum. Gibson et ai. (1984) reported for the rat muscarinic acetylcholine receptor with [3H]3-quinuclidinyl benzilate a peak-shaped striatal/cerebellar ratio curve due to binding to cerebellar sites. Low density dopamine D2 sites in the cerebellum have recently been reported in the baboon with 18p_ spiperone (Logan et aI., 1987) , in the rat brain with e 2 5I]iodosulpride (Martres et aI., 1985a,b ; Van der Werf et aI., 1986) , and in mice with eH]spiperone (Panagopoulos et aI., 1988) . Preliminary binding re sults with e lC]NMSP from our lab confirm the ex istence of cerebellar sites. The sigmoidicity cannot be due to the presence of mUltiple sites (COM2 model) because binding to two independent sites leads generally to a Hill coefficient lower than unity. This is clearly not the case. Competing en dogenous dopamine as an alternative mechanism for the appearance of sigmoidicity is not very likely. In vivo binding of eH]spiperone in dopamine depleted (6-hydroxydopamine-treated) rats was not changed (Van der Werf et aI., 1984) . In addition, the affinity of dopamine is much lower than that of spip-erone (Seeman, 1980) , and competition does gener ally not lead to sigmoid curves.
In vivo binding of H C-Iabeled NMSP
The peak-shaped distribution of the striatal ratios at low doses of [l1C]NMSP confirms the occurrence of sigmoidicity in the striatal spiperone binding data. The complete disappearance of the peak after pretreatment with haloperidol indicates the dopami nergic character of the peak. An initially rising ratio in the striatum but not in the cortex was recently reported for eHlNMSP in mice (Frost et aI. , 1987) .
In contrast to these data and to our spiperone data, a peak-shaped ratio distribution was found for the binding of [l1C]NMSP in the frontal cortex. The occurrence of sigmoidicity due to cerebellar sites is expected to vary under different circumstances (see Appendix). Thus, the varying appearance of the ra tio peak in the frontal cortex and the finding that haloperidol treatment leads to a disappearance of the e lC]NMSP ratio peak but not to a complete reduction of binding can be better understood with the RCS than with the TIS model. Preliminary re sults indicate that an initially rising ratio curve also exists for e lC]NMSP binding in the human brain (Swart et aI. , 1989) .
CONCLUSIONS
In contrast to that in the frontal cortex, sigmoid binding is found for spiperone in the rat striatum. Consequently, the plot of the striatal/cerebellar ac tivity ratio versus the overall cerebellar binding is peak shaped. High values for the B m ax of spiperone binding in the rat striatum are found, which may indicate the existence of an extra receptor pool not detectable with in vitro techniques. A peak-shaped distribution is also found for the striatal and frontal cortical/cerebellar ratio of [l1C]NMSP. Cerebellar high-affinity/low-capacity sites may cause this fea ture. The ROI/cerebellar ratio is generally used as an index for specific and nonspecific binding kinet ics in PET studies. When the peak-shaped ratio curve of spiperone and e lC]NMSP applies to the human brain, low-dose ratios will not reflect spe cific binding parameters accurately. Our results in dicate that the assumption of negligible specific binding in the cerebellum in current dopamine re ceptor models is challenged when low-dose ratios are determined. Whether or not the human brain behaves as the rat brain with respect to this feature has yet to be demonstrated, and PET studies may be useful for that purpose.
J Cereb Blood Flow Metab, Vol. 10, No. 3, 1990 APPENDIX: THE ROI CEREBELLAR SITES
MODEL (RCS MODEL)
The total binding in the ROI with noninteracting sites is given by B max Lt = 1 + KdlL + (1 + j)L (AI ) as defined in Table 1 . 
where 8(Lt c ) is the numerator of Eq. A4, P = (1 + fc)Kdlk, and <I> = k(1 + f)1(1 + fc). The function described by Eq. A5 is sigmoid if the ratio, defined as R = LtiLt c , is initially rising (in preparation). The limitLt ->0 (dRldLTc > 0) results for Eq. A5 in a condition for the appearance of a sigmoid curve:
1 + <I>(PIB max) PclP < I + P IB c max c Clearly, the occurrence of sigmoidicity depends on the values of all parameters involved in the RCS model and may vary under different conditions that lead to other parameter values, e. g. , the occurrence of competition and nonspecific binding.
